Takahiro Mukahira of MP Healthcare Venture Management will be a board observer at GenKyoTex.

GenKyoTex, a Switzerland-based biotechnology company to treat diabetes, has raised SFr18m ($20m) in its series C round from a consortium including as a new investor MP Healthcare Venture Management, a US-based life sciences venture capital firm affiliated with Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Chemical Holdings Corporation (MCHC).

Venture capital firm Edmond de Rothschild Investment Partners (EdRIP) led the C round, which also included peers Vesalius Biocapital Partners and SEFTI (Specialized European Fund for Therapeutic Innovation) and incubator…